Correction: Peptonic Medical’s Annual Report 2024 published

In Peptonic Medical's annual report for 2024, there was a remark in the audit report: "We draw attention to the administration report, which states that the company has reported losses for several years in a row and under the heading "Earnings capacity, future capital requirements and continued operations" in the administration report and Note 2, it is stated that the company has strained liquidity, that liquidity is assessed as insufficient and that the company applied for corporate reconstruction in March 2025. These circumstances indicate that there are material uncertainties that may lead to significant doubt about the company's ability to continue operations. We have not modified our opinions on this basis."

The annual report is available in Swedish in PDF format on the company website at: https://www.peptonicmedical.se/en/financial-information/

For further information please contact:

Anna Linton, CEO of Peptonic Medical AB

E-mail: anna.linton@peptonicmedical.se

Phone: +46 70-244 92 07

About PEPTONIC medical AB

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

Läs mer på Cision